
Russian scientists have begun producing mRNA-based cancer vaccines - Photo: AFP
On December 11-12, Alexander Gintsburg, Director of the Gamaleya Institute (*) in Moscow, announced that Russian scientists had produced the first three test batches of a new cancer vaccine developed by the country.
The vaccine batches "passed all quality checks" even though they are still in the testing phase.
"Most importantly, our leading cancer center, the Herzen Institute, has received all the necessary approvals to use this technology, from diagnosis and mRNA production to injection into patients," RT quoted Gintsburg as saying.
Information about the new cancer vaccine was first released in September 2025. This is a personalized treatment designed to target malignant tumors using the patient's own genetic information.
Developed with the help of artificial intelligence, the mRNA platform allows each dose to be tailored to an individual's cancer profile, potentially leading to more precise and effective therapy.
Preclinical studies suggest the drug may reduce tumor size and slow its growth by 60-80%, depending on the patient. The vaccine is initially intended for use in patients with colorectal cancer.
Unlike conventional vaccines, mRNA cancer vaccines are a new class of therapies used to treat late-stage cancer. They are called "vaccines" because they affect the immune system, training it to recognize and destroy tumor cells.
Last month, the Russian Ministry of Health also authorized the use of two cancer vaccines: NeoOncoVak, an mRNA-based therapeutic vaccine for melanoma, and Oncopept, a vaccine for malignant tumors.
(*) The Gamaleya Institute is internationally renowned for developing Sputnik V, Russia's COVID-19 vaccine.
Source: https://tuoitre.vn/nga-san-xuat-3-lo-vac-xin-ung-thu-mrna-dau-tien-20251211231125336.htm






Comment (0)